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Summary
 
The chemokine receptors CXCR4, CCR2B, CCR3, and CCR5 have recently been shown
to serve along with CD4 as coreceptors for HIV-1. The tropisms of HIV-1 strains for sub-
groups of CD4
 
1
 
 cells can be explained, at least partly, by the selective use of G protein–cou-
pled receptors (GPCRs). We have identified a novel human gene, 
 
STRL33
 
, located on chro-
mosome 3 that encodes a GPCR with sequence similarity to chemokine receptors and to
chemokine receptor–like orphan receptors. 
 
STRL33
 
 is expressed in lymphoid tissues and acti-
vated T cells, and is induced in activated peripheral blood lymphocytes. When transfected into
nonhuman NIH 3T3 cells expressing human CD4, the 
 
STRL33
 
 cDNA rendered these cells
competent to fuse with cells expressing HIV-1 envelope glycoproteins (Envs). Of greatest in-
terest, STRL33, in contrast with CXCR4 or CCR5, was able to function as a cofactor for fu-
sion mediated by Envs from both T cell line–tropic and macrophage-tropic HIV-1 strains.
 
STRL33
 
-transfected Jurkat cell lines also supported enhanced productive infection with HIV-1
compared with control Jurkat cells. Despite the sequence similarities between STRL33 and
chemokine receptors, 
 
STRL33
 
-transfected cell lines did not respond to any in a panel of
chemokines. Based on the pattern of tissue expression of the 
 
STRL33
 
 mRNA, and given the
ability of STRL33 to function with Envs of differing tropisms, STRL33 may play a role in the
establishment and/or progression of HIV-1 infection.
 
T
 
he seven transmembrane domain G protein–coupled
receptors (GPCRs)
 
1
 
 constitute a large family of pro-
teins that signal in response to agonists as diverse as poly-
peptide hormones, neurotransmitters, odorants, light, and
cytokines (1, 2). Within this superfamily is the group of re-
ceptors for the chemokines, cytokines that are produced by
many tissues and cell types and whose best-described activ-
ities are as chemotactic factors for leukocytes, including
lymphocytes (3). To date, 10 human receptors that signal in
response to chemokines have been described, designated by
the most recent nomenclature CXCR1–4 for the receptors
for chemokines in the CXC subfamily and CCR1, 2A, 2B,
and 3–5 for the receptors for chemokines in the CC sub-
family. In addition, a number of orphan GPCRs have been
identified whose sequences suggest that they may be recep-
tors for as yet unidentified chemokines (4).
Recent work has revealed novel relationships between
chemokines–chemokine receptors and infection with HIV-1.
Understanding these relationships has shed light on mecha-
nisms of HIV-1 entry into cells and on the tropisms of
HIV-1 strains for specific populations of CD4
 
1
 
 cells. All
HIV-1 strains can infect primary T cells. However, as a result
of differences among their envelope glycoproteins (Envs),
some HIV-1 strains are able to infect macrophages (M-tropic)
but not immortalized T cell lines; some, among them labo-
ratory-adapted strains, are able to infect immortalized T cell
lines (TCL-tropic) much more efficiently than they infect
macrophages; and some strains are readily able to infect
both types of cells. Analysis of clinical HIV-1 isolates sug-
gests that M-tropic strains are critical for establishing and
maintaining infection (reviewed in references 5, 6).
The CC chemokines MIP-1
 
a
 
, MIP-1
 
b
 
, and RANTES
were found to suppress infection of lymphocytes by M-tropic
HIV-1 strains (7). This report was followed by the func-
tional cDNA cloning of a cofactor (designated fusin) that,
along with CD4, mediates fusion and entry of TCL-tropic
HIV-1 strains (8). Fusin, previously identified as an orphan
 
1
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GPCR, has recently been shown to be a receptor for the
CXC chemokine SDF-1 and has been renamed CXCR4
(9, 10).
The discovery of the activity of CXCR4 was followed
by the demonstration that chemokine receptor CCR5 can
function as a cofactor with CD4 for cell fusion and/or viral
entry and infection by M-tropic strains of HIV-1 (11–16).
CCR5 has been demonstrated to play a critical role in the
establishment of HIV-1 infection, because homozygosity
for an allele encoding a fusion-defective CCR5, present in
 
z
 
1% of the Caucasian population, is strongly associated
with resistance to HIV-1 infection (17–20). Nonetheless,
HIV-1 infection has been reported in an individual ho-
mozygous for the defective CCR5 gene (21), indicating
that under some circumstances CCR5 is not essential for
infection. Identifying the range of coreceptors that can be used
by HIV-1 is important, particularly if therapies targeting
specific coreceptors place the virus under selective pressure.
As part of studies on the roles of chemokines in lympho-
cyte biology, we designed experiments to identify novel
chemokine receptors in human T cells. In this report, we
describe the molecular cloning of a cDNA for 
 
STRL33
 
, a
gene encoding a GPCR related to known chemokine re-
ceptors that is expressed in lymphoid tissues and activated
T cells, and is induced in activated PBL. We demonstrate
that STRL33, in marked contrast with CXCR4 and CCR5,
can function with CD4 as a cofactor for cell fusion medi-
ated by Envs of both M-tropic and TCL-tropic strains of
HIV-1 and we show that transfection with 
 
STRL33
 
 signif-
icantly enhances the ability of Jurkat cells to support pro-
ductive infection with HIV-1. These data suggest that
STRL33 may play a role in the establishment and/or the
course of HIV-1 infection.
 
Materials and Methods
 
Cell Culture.
 
Jurkat, SUP-T1, U937, human embryonic kid-
ney (HEK) 293, HeLa, and NIH 3T3 cells were obtained from
American Type Culture Collection (ATCC, Rockville, MD).
CEM clone 12D7 was obtained from Dr. G. Poli (National Insti-
tute of Allergy and Infectious Diseases, National Institutes of
Health). Tumor-infiltrating lymphocytes (TIL) R4, R8, F9, and
B10, prepared from human melanomas, were obtained from Dr.
J.R. Yannelli (National Cancer Institute). EBV414 is an EBV-
transformed B lymphoblastoid cell line obtained from Dr. R. Sili-
ciano (Johns Hopkins University). Jurkat, SUP-T1, CEM, U937,
and EBV414 cells were grown in RPMI-1640 with 10% fetal bo-
vine serum (FBS). Elutriated PBL and monocytes were obtained
from a normal donor by the Department of Transfusion Medicine
(National Institutes of Health), and PBL were purified further by
banding on Ficoll–Paque. For activation, 5 
 
3
 
 10
 
6
 
 PBL/ml were
cultured with 10 
 
m
 
g/ml PHA-P and 1 
 
m
 
M ionomycin for 3 d be-
fore harvesting for RNA. 293 cells were grown in MEM plus
10% horse serum. HeLa and NIH 3T3 cells were grown in
DMEM with 10% FBS. TIL were grown in either RPMI-1640
with 10% FBS or in AIM-V (GIBCO BRL, Gaithersburg, MD),
in each case supplemented with 500 U/ml IL-2, and the cells
were stimulated periodically with 250 ng/ml PHA plus irradiated
allogeneic PBMC.
 
Cloning of STRL33 cDNAs.
 
Total RNA was prepared from
the F9 TIL using TRIzol reagent (GIBCO BRL, Gaithersburg,
MD), poly(A)
 
1
 
 RNA was selected using oligo(dT) cellulose (Col-
laborative Biomedical Products, Bedford, MA), and first-strand
cDNA was synthesized using oligo(dT) primers and the Super-
Script Preamplification System (GIBCO BRL) according to the
instructions of the manufacturer. For amplification, primer pools
were designed based on transmembrane domain (TMD) II and
TMD VII amino acid sequences from the human sequences for
IL-8RA, IL-8RB, CCR1, and CCR2 and the murine homo-
logues of IL-8RB and CCR1 and were 5
 
9
 
-GA(T/C)(C/T)TI(C/
T/G)TITT(T/C)(G/T/C)(C/T)I(T/C/A)TIACI(T/C)TICC, and
5
 
9
 
-CCIA(T/C)(A/G)AAI(G/A)(C/T)(A/G)TAIA(T/A/G)IA(G/
A/T/C)IGG(A/G)TT, respectively. Amplifications were done
with cDNA synthesized from 0.015 
 
m
 
g of poly(A)
 
1
 
 RNA, with
1.5 
 
m
 
M of each primer pool in a 20 
 
m
 
l reaction volume with Taq
polymerase and reagents from Perkin Elmer (Norwalk, CT), ac-
cording to the instructions of the manufacturer. PCR was done
using 30 cycles of denaturation at 94
 
8
 
C for 0.5 min, annealing at
45
 
8
 
C for 2 min, and chain extension at 72
 
8
 
C for 1.5 min.
 1 
 
m
 
l from the first PCR was used in a second PCR done
identically to the first and the products of the second reaction
were separated on a 1.5% agarose gel from which fragments of
the predicted size of 
 
z
 
670 bp were purified and inserted by blunt
end ligation into the vector pNOTA/T7 (5
 
9
 
 3
 
9
 
 Prime, Inc.,
Boulder, CO). 88 ampicillin-resistant bacterial transformants were
picked and, to eliminate known sequences, hybridizations were
done with radiolabeled oligonucleotide probes for receptors
 
CCR1
 
, 
 
CCR2
 
, 
 
CCR3
 
, 
 
CXCR4
 
, 
 
BLR1
 
, 
 
EBI1
 
 and 
 
STRL22.
 
Among the inserts in the nonhybridizing colonies was a novel se-
quence designated 
 
STRL33.
 
Using poly(A)
 
1
 
 RNA from F9 TIL a 
 
l
 
 ZAP Express (Strat-
agene, La Jolla, CA) cDNA library was prepared according to the
instructions of the manufacturer. 1.4 
 
3
 
 10
 
6
 
 recombinant phages
from the nonamplified library were screened using a radiolabeled
 
STRL33
 
 probe. 10 positive phages were plaque-purified and the
pBK-CMV (Stratagene, La Jolla, CA) plasmids containing 
 
STRL33
 
inserts were recovered by in vivo excision according to the in-
structions of the manufacturer. Manual and/or automated dideoxy
sequencing was done for the entire cDNA clone 
 
STRL33.
 
1, the
5
 
9
 
 nontranslated region of clone 
 
STRL33.
 
2, the 5
 
9
 
 nontranslated
region and open reading frame (ORF) of clone 
 
STRL33
 
.3, and
portions of other cDNA clones, some of which were obtained
using RT–PCR.
 
Northern Blot Analysis.
 
Total RNA was prepared as above.
DNAs used for probes were the following: 
 
IL8RA
 
, 
 
IL8RB
 
,
 
CCR3
 
, 
 
EBI1
 
, and 
 
BLR1
 
 genomic fragments and 
 
CCR2B
 
 cDNA
obtained from Dr. P. Murphy (National Institute of Allergy and
Infectious Diseases); 
 
STRL33
 
, 
 
CCR1
 
, 
 
CCR4
 
, 
 
CCR5
 
, 
 
CXCR4
 
,
and 
 
CMKBRL1
 
 cDNAs that we isolated either from our 
 
l
 
 library
or by RT–PCR from TIL mRNA; and an 
 
STRL22
 
 genomic
fragment isolated as described (22). Hybridizations to leukocyte
RNA were performed as described with washes in 0.1
 
3
 
 SSC,
0.1% SDS at 50
 
8
 
C (23). Hybridizations with an oligonucleotide
probe to 18S rRNA were as described (24). The blot of poly(A)
 
1
 
RNA from human tissues was obtained from Clontech (Palo
Alto, CA). Hybridizations were done according to the instruc-
tions of the manufacturer with washes as described above. Auto-
radiography/fluorography was done using an intensifying screen.
 
Production and Analysis of STRL33-transfected Cell Lines.
 
An EcoRI–
EarI fragment containing the complete 
 
STRL33
 
 ORF was iso-
lated from the pBK-CMV/
 
STRL33
 
.1 plasmid and inserted into
pCEP4 (Invitrogen, Carlsbad, CA) and pCIneo (Promega Corp., 
2017
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Madison, WI). The pCIneo/
 
STRL33
 
 DNA was transfected into
HEK 293 cells by calcium phosphate precipitation (25) and the
pCEP4/
 
STRL33
 
 DNA and pCEP4 without a cDNA insert were
transfected into Jurkat cells by electroporation (26). Selection was
in 200 
 
m
 
g/ml hygromycin B (Sigma, St. Louis, MO) and 1 mg/ml
G418 (GIBCO BRL, Gaithersburg, MD) for pCEP4-transfected
cells and pCIneo-transfected cells, respectively. Individual colo-
nies of resistant 293 cells were cloned and expanded and Jurkat
lines were derived by limiting dilution after the electroporation.
Lines expressing the highest levels of 
 
STRL33
 
 mRNA were used to
test responses to chemokines using the fluorometric calcium flux
assay as described (27), or for infection with HIV-1 as described
below. Recombinant HuMig was obtained by infecting High
Five cells of 
 
Trichoplusia ni
 
 (Invitrogen, Carlsbad, CA), as will be
described elsewhere, and was purified by column chromatography
as described (27). IP-10, MCP-1, MCP-2, MCP-3, RANTES,
MIP-1
 
a
 
, MIP-1
 
b
 
, platelet factor 4, IL-8, and lymphotactin were
purchased from Pepro Tech (Rocky Hill, NJ). MCP-4 was a gift
from Dr. A. Luster (Harvard University). I309 and SDF-1 were
gifts from R&D Systems (Minneapolis, MN).
 
Assays for Activity of STRL33 as a Fusion Cofactor.
 
Assays were
done using a vaccinia-based 
 
Escherichia coli lacZ
 
 reporter gene assay
for fusion between two cell populations, one expressing an HIV-1
Env and the other expressing CD4 (28). Vaccinia-mediated expres-
sion of GPCRs was achieved by transfection of 7 
 
3
 
 10
 
6
 
 NIH
3T3 cells using DOTAP lipofectin (Boehringer Mannheim, Indi-
anapolis, IN) with 10 
 
m
 
g of plasmids containing DNA encoding
the GPCRs linked to the bacteriophage T7 promoter. The plas-
mid vectors were pCIneo (Promega Corp., Madison, WI) for
STRL33 and pCDNA3 for CXCR4 (8) and CCR5 (11); as a
negative control, pCIneo lacking an insert was used. After 4–5 h,
the transfected cells were infected at 10 PFU/cell with recombi-
nant vaccinia viruses vCB-3 encoding human CD4 (29) and vTF7-3
encoding T7 RNA polymerase (30). A separate population of
HeLa cells was coinfected with vaccinia virus vCB-21R–LacZ
containing 
 
lacZ
 
 encoding 
 
b
 
-galactosidase (
 
b
 
-Gal), under control
of a T7 promoter (31) and one of the following Env-encoding vac-
cinia viruses: vCB-41 encoding the LAV (NL4.3) Env (32), vCB-39
encoding the ADA Env (32), vCB-28 encoding the JR-FL Env
(32), vCB-32 encoding the SF-162 Env (32), vCB-43 encoding
the Ba-L Env (32), vSC60 encoding the IIIB Env (Chakrabarti,
S., and B. Moss, personal communication), and vCB-16 encod-
ing the nonfusogenic Unc Env (32). For experiments using the
89.6 Env, before infection with vCB-21R–LacZ, HeLa cells
were transfected with 10 
 
m
 
g of the pSC59 plasmid (Chakrabarti,
S., and B. Moss, personal communication) containing DNA en-
coding the 89.6 Env (33), a gift of R. Collman (University of
Pennsylvania School of Medicine). Infected cells were incubated
overnight at 31
 
8
 
C. Duplicate samples of 10
 
5
 
 NIH 3T3 target cells
and 10
 
5
 
 Env-expressing cells were mixed; after 2.5 h cells were
lysed and 
 
b
 
-Gal activity was measured as described (28).
 
Infectivity Assay for HIV-1.
 
Virus stocks of HIV-1
 
ELI1
 
 were pre-
pared by transfection of 293 cells with molecular clone pELI1
(34), and the amount of virus was determined by RT activity
(35). 2 
 
3
 
 10
 
6
 
 cells of the Jurkat cell lines were infected with the
amount of virus corresponding to 10
 
5 cpm of RT activity as de-
scribed (35). Virus production was measured by the appearance of
RT activity in the medium.
Results and Discussion
To identify novel chemokine receptors expressed in T cells,
we used RT–PCR with poly(A)1 RNA prepared from
TIL line F9 and pools of degenerate primers based on con-
served sequences in the TMDs of known chemokine re-
ceptors. We isolated a sequence encoding a novel GPCR,
designated STRL33, for seven TMD receptors from lym-
phocytes clone 33. Southern blot analysis of human ge-
nomic DNA digested with BamHI, HindIII, and PstI re-
vealed a single STRL33 gene, and using STRL33-specific
primers and DNA prepared from a panel of human–ham-
ster hybrid cell lines, STRL33 was localized to chromo-
some 3 (data not shown). This raises the possibility that
STRL33 is in the cluster of genes for chemokine receptors
CCR1, 2, 3, and 5 at 3p21, although the CCR proteins
show .50% amino acid identity among themselves, dem-
onstrating significantly closer relationships than what is seen
in comparisons with STRL33 (see below).
Screening of a nonamplified l cDNA library prepared
from F9 TIL revealed an abundance for STRL33 mRNA
of z0.01%. 10 cDNA clones were isolated and by restriction
enzyme digestion, three size classes were identified. Repre-
sentative cDNAs from each class, STRL33.1, STRL33.2,
and STRL33.3, respectively, were evaluated in more detail
by restriction analysis and partial sequencing, revealing that
size differences among the clones were due to 59 nontrans-
lated regions that differed not only in length but in their se-
quences. The complete sequence of STRL33.1, the se-
quence of the 59 nontranslated region of STRL33.2, and
the sequence of the 59 nontranslated region and ORF of
STRL33.3 have been submitted to GenBank with accession
numbers U73529, U73530, and U73531, respectively.
STRL33.1 contained 1,897 nucleotides, excluding the
poly(A) tail, with an ORF encoding a predicted protein of
342 amino acids (Fig. 1). The predicted initiator codon was
in a favorable context for initiation (36) and could be as-
signed unambiguously because, with the reading frame
fixed by comparison with other GPCRs, it was the first
ATG after an in-frame stop codon in cDNA STRL33.3,
and it was also the first in-frame ATG in cDNAs STRL33.1
and STRL33.2. As noted above, ORF sequence was also
determined from cDNAs other than STRL33.1, and the se-
quence of the entire STRL33.1 ORF was confirmed in in-
dependent clones. However, differences were noted between
the ORFs of STRL33.1 and STRL33.3 at two positions: a
second position change in the 25th codon of STRL33.3
(GAC ® GCC), replacing D25 with A, and a silent third
position change in the 103rd codon of STRL33.3 . The si-
lent change in the 103rd codon of STRL33.3 was present in
a second independent clone, whereas the 25th codon
change has not been independently verified. We presume
that at least the silent change represents a true polymorphism
in the F9 TIL. The 59 nontranslated regions of STRL33.1,
STRL33.2, and STRL33.3 were 30, 135, and 1,462 nucle-
otides, respectively, and sequence comparisons revealed
that differences among these regions were due, at least in
part, to alternative splicing (data not shown). Not surpris-
ingly, the long additional 59 nontranslated sequence of
STRL33.3 contained many ATG sequences (but no signifi-
cant ORFs), suggesting that the STRL33.3 mRNA may
not be translated efficiently, and although we could detect a2018 STRL33, A Novel Fusion Cofactor for Diverse HIV-1 Strains
STRL33.3-specific mRNA by Northern blot analysis (see
below), the STRL33.3 cDNA may be derived from an in-
completely processed mRNA. Extensive processing, yield-
ing mRNAs with alternative 59 exons, is well documented
among the chemoattractant receptors (2), and incomplete
processing of mRNAs in lymphocytes has been suggested
as a possible mechanism for the regulation of translation (37).
Comparison of STRL33 with sequences in the GenBank
database as of March 30, 1997, using BLAST (38) revealed
no identical sequences but greatest similarity to orphan
GPCRs and related chemokine receptors. Matches were
found between sequences in the 39 nontranslated region of
STRL33 and several sequences in the EST database for which
no significant homologies had been identified. Alignments
between STRL33 and selected related sequences is shown
in Fig. 1. Percent identities between STRL33 and orphan
receptors STRL22 (22), GPR-9-6 (GenBank accession num-
ber U45982), and EBI1 (39) are 37, 32, and 32%, respectively,
and between STRL33 and chemokine receptors IL-8RB
(CXCR2), CXCR4, CCR3, CCR5, and IL-8RA (CXCR1)
are 30, 30, 30, 29, and 28%, respectively. STRL22 is an or-
phan receptor gene that, like STRL33, was isolated from
the F9 TIL (22).
Fig. 1 shows that similarities among the receptors are
greatest in the TMDs, as is typical of GPCRs. Like other
GPCRs, STRL33 includes a site for N-linked glycosyla-
tion in the NH2-terminal domain (N16), cysteines in extra-
cellular loops one and two (C102 and C180), and multiple
serines in the COOH terminal domain (1). While there is
no signature sequence motif for the chemokine receptors,
the STRL33 sequence does contain some features charac-
teristic of chemokine receptors, including an acidic NH2-
terminal domain with paired acidic residues (E8 and D9,
E21 and E22) (2), a short basic third intracellular loop, an
alanine in place of the proline that is conserved in non-
chemokine receptor GPCRs in the second intracellular
loop (A134), a paired cysteine and tyrosine in TMD V
(C210 and Y211), and a cysteine in TMD VII (C282). In
contrast, some residues typical for chemokine receptors are
absent from STRL33, including cysteine residues in the
NH2-terminal domain and in the third extracellular loop.
Multiple sequence alignment (PileUp, Genetics Computer
Group, Madison, WI) places STRL33 in a group of orphan
receptors, including STRL22, GPR-9-6, and EBI1, sepa-
rate from the groupings of the CXCRs on one hand and
the CCRs on the other (data not shown).
We analyzed RNA expression by Northern blot of total
RNA for STRL33 and other related receptors in leukocyte
Figure 1. Alignment of the STRL33 predicted amino acid sequence with the selected GPCRs STRL22, GPR-9-6, EBI1, IL-8RB, CXCR4, CCR3,
CCR5, and IL-8RA. Numbers at the right indicate the positions of the residues at the end of each line of sequence. Solid backgrounds highlight matches
between STRL33 and the other receptors. Dots indicate gaps introduced for optimal alignments. Putative TMDs I–VII are indicated by bars. The align-
ments were generated using the PileUp program of the Wisconsin Sequence Analysis Package of Genetics Computer Group (Madison, WI).2019 Liao et al.
populations and lines and in human tissues. As shown in
Fig. 2 A, the STRL33 cDNA probe hybridized to a broad
band at z2 kb that was prominent in both CD41 (R4, F9,
and B10) and CD81 (R8) TIL with low level signal in PBL
but not in other cells tested, including immortalized CD41
T cell lines. Using a probe from the 59 nontranslated se-
quences specific for the STRL33.3 mRNA, we also de-
tected a band at z3.6 kb in the F9 and B10 TIL after long
exposure, not shown in Fig. 2 A. Fig. 2 B demonstrates that
in vitro activation of PBL induces expression of STRL33 to
levels comparable to that seen in the TIL.
Fig. 2 A shows significant differences in expression of
various chemokine receptor and orphan receptor genes
among the leukocytes. Of particular interest is the demon-
stration of heterogeneity of receptor gene expression among
T cell preparations. In general, receptor gene expression is
higher among the TIL than in T cell lines or freshly iso-
lated PBL, although even among the TIL there are signifi-
cant differences. For example, the CD41 F9 TIL show a
significant signal for CCR3. This is noteworthy, because
although CCR3 can serve in vitro as a coreceptor for HIV-1
(13), speculation on a role for CCR3 in systemic HIV-1
infection has been constrained by the assumption that
among leukocytes CCR3 expression is limited to eosino-
phils.
Fig. 3 shows the expression of the STRL33 gene in se-
lected human tissues. There is an mRNA species of z2.1
kb prominently expressed in lymphoid tissue; a species of
z2.5 kb in placenta; low abundance species of 2.1-2.4 kb
expressed in pancreas, liver, lung, and heart; and low abun-
dance larger species in a variety of tissues. The conspicuous
expression of the STRL33 gene in T cells, activated PBL,
and lymphoid tissues is consistent with the presumption
that STRL33 is a chemokine receptor.
HEK 293 cells were transfected with an expression vec-
tor containing the STRL33.1 ORF, and cell lines were de-
rived as described in Materials and Methods. Cell lines ex-
pressing the highest levels of STRL33 RNA were tested in
a fluorometric calcium flux assay for responses to chemo-
kines. The STRL33-transfected cells were tested with platelet
factor 4, IL-8, IP-10, HuMig, SDF-1, MIP-1a, MIP-1b,
RANTES, MCP-1, MCP-2, MCP-3, MCP-4, I309, and
lymphotactin, and no responses were found.
The demonstrations that receptors for both CXC and
CC chemokines can function as cofactors for HIV-1 entry
into cells led us to test STRL33 in an assay designed to de-
Figure 2. Expression of STRL33
and other GPCR genes. (A) The
expression of STRL33, genes for
known chemokine receptors,
and genes for selected orphan
GPCRs in leukocytes. 15 mg of
total RNA were electrophoresed
on 1.2% agarose–formaldehyde
gels, transferred to nitrocellulose
membranes, and hybridized with
the probes indicated on the left.
A total of six membranes were
used for hybridizations, and ade-
quate removal of signal was doc-
umented before repeat probings.
Film exposure times ranged from
overnight for the IL-8RA and
IL-8RB blots to 13 d for the
CXCR4 blot. Probings were
done using an oligonucleotide
complementary to 18S rRNA in
order to demonstrate amounts of
RNA loaded per lane and a rep-
resentative blot is shown. (B)
The expression of STRL33 in
activated PBL. 25 mg of total
RNA from TIL, and freshly iso-
lated and activated PBL were an-
alyzed as in A and hybridized
with a 32P-labeled STRL33 ORF
probe and a probe for 18S rRNA.2020 STRL33, A Novel Fusion Cofactor for Diverse HIV-1 Strains
tect fusion between two cell populations: NIH 3T3 cells
expressing T7 RNA polymerase, human CD4, and either
STRL33 or CXCR4 or CCR5 , and HeLa cells expressing
Envs from HIV-1 isolates with differing tropisms. Fusion
between the two cell populations resulted in expression of
b-Gal. As a negative control, we used the Unc Env, a mu-
tant protein that cannot mediate fusion due to a deletion of
the gp120/gp41 cleavage site.
The results of the fusion assays are shown in Fig. 4. In
Fig. 4 A, NIH 3T3 cells expressing CD4 plus CXCR4
fused well with cells expressing Envs from TCL-tropic
LAV (NL4.3) and IIIB, whereas with Envs from the M-tropic
strains only weak (ADA) or negligible (SF162, Ba-L, and
JR-FL) fusion was observed. Cells expressing CD4 plus
CCR5 showed the opposite specificity: they fused well
Figure 3. The expression of STRL33 in human tissues. Blots were pre-
pared by the supplier (Clontech, Palo Alto, CA) from 1.2% agarose–form-
aldehyde gels containing z2 mg poly(A)1 RNA per lane. Hybridizations
were done using a 32P-labeled STRL33 ORF probe and blots were
Figure 4. Activity of STRL33 as a fusion cofactor. (A) NIH 3T3 cells
were transfected with DNAs encoding CXCR4 or CCR5 or STRL33,
and infected with vaccinia recombinants encoding CD4 and T7 RNA
polymerase. HeLa cells were infected with a vaccinia recombinant con-
taining lacZ under control of a T7 promoter and infected separately with
vaccinia recombinants encoding the indicated Envs. Unc is a mutant Env
that cannot be cleaved to gp120 and gp41 and cannot mediate fusion.
Cell fusion was quantified by measuring b-Gal activity. NIH 3T3 cells
transfected with the STRL33 cDNA but not infected with virus vCB-3
encoding CD4 did not fuse with cells expressing any of the Envs (data not
shown). Results of one experiment are shown. STRL33 also mediated fu-
sion with cells expressing both TCL-tropic and M-tropic Envs in four ad-
ditional experiments. (B) Cell fusion experiment done as in A, except that
here the DNA encoding the Env, 89.6, was introduced into HeLa cells by
transfection of plasmid DNA, resulting in lower levels of fusion overall as
compared with A. The value obtained for Unc has been subtracted from
each of the values obtained using the 89.6 Env. Results are shown from
one experiment. Similar activity for STRL33 was found in another ex-
periment using the 89.6 Env.
washed according to the instructions of the manufacturer. The blot pre-
pared from lymphoid tissue (left) was exposed for 2 d, and the blot from
other selected tissues (right) was exposed for 8 d.2021 Liao et al.
with cells expressing the Envs from the M-tropic strains
ADA, SF162, Ba-L, and JR-FL and not the Envs from
TCL-tropic LAV (NL4.3) and IIIB. These results are con-
sistent with previous reports (8, 11–15).
In contrast with the restricted specificities of CXCR4
and CCR5, STRL33 functioned with CD4 as a fusion co-
factor for cells expressing Envs from both TCL-tropic and
M-tropic strains. Additionally, as shown in Fig. 4 B, STRL33,
like CXCR4 and CCR5, mediated fusion with the dual-
tropic Env 89.6. Negligible b-Gal activity, equivalent to
levels seen using the Unc Env, was detected in fusion assays
using CD4-expressing NIH 3T3 cells transfected with a
control vector lacking the STRL33 cDNA insert, or in as-
says using NIH 3T3 cells transfected with the STRL33
cDNA but not expressing CD4 (data not shown).
We tested the ability of STRL33 to support productive
infection with HIV-1. We transfected Jurkat cells, which
express CD4 and CXCR4, but not other known HIV-1
coreceptors, with vector containing the STRL33.1 cDNA,
or with vector control, and cell lines were derived under
selection by limiting dilution. We infected the STRL33-
transfected and control cells with HIV-1ELI1, a molecularly
cloned isolate with properties of a primary virus (34, 40,
41). HIV-1ELI1 has been shown to grow poorly in Jurkat
cells (34) and CXCR4 does not function efficiently as a co-
receptor for the HIV-1ELI1 Env (13). As shown in Fig. 5,
the STRL33-transfected cells supported productive infection
with HIV-1ELI1 under conditions where control transfected
cells yielded no detectable virus. Although in experiments
using higher innocula of virus, HIV-1ELI1, as reported (34),
could infect cultures of control Jurkat cells, the activity of
STRL33 was also clear in these experiments, because HIV-
1ELI1 production by the control cultures lagged significantly
behind HIV-1ELI1 production in cultures of STRL33-trans-
fected cells (data not shown). Enhanced infection with
HIV-1ELI1 in STRL33-transfected Jurkat cells was demon-
strated in four experiments using a total of three indepen-
dent STRL33-transfected cell lines.
The identification of STRL33 adds to the recent discov-
eries on the roles of chemokine receptors in the pathobiol-
ogy of HIV-1 infection. STRL33 is a novel GPCR that
can function with CD4 to mediate fusion with cells bearing
HIV-1 Envs from laboratory-adapted TCL-tropic, M-tropic,
and dual-tropic strains. In this regard, STRL33 can mediate
fusion with a wider range of Envs than can the major co-
factors CXCR4 and CCR5. Recent literature has sup-
ported the strong correlation between assays for Env/core-
ceptor–mediated fusion and infection (8, 11–16), and we
have demonstrated that STRL33 can significantly enhance
the ability of HIV-1 to infect cells. While the role of
STRL33 in the biology of viral infection is unknown, the
STRL33 gene is expressed in cells and tissues that are
among the natural targets for HIV-1. Further work will de-
termine whether STRL33 represents an important host
component in the transmission of HIV-1 and the progres-
sion of AIDS.
Figure 5. HIV-1 infection of STRL33-transfected Jurkat cells. 2 3 106
cells were infected with HIV-1ELI1 corresponding to 105 cpm of RT ac-
tivity. Samples were taken every 2 d for determining RT activity from
cultures of the control-transfected Jurkat cell line JC0.1 (j) and from cul-
tures of the STRL33.1-transfected Jurkat cell line JC3.9 (m).
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